RESULTS	By contrast , there were no significant differences by treatment group for patients with EGFR Leu858Arg-positive tumours in either trial : in LUX-Lung 3 , median overall survival was 27.6 months ( 19.8-41 .7 ) in the afatinib group versus 40.3 months ( 24.3-not estimable ) in the chemotherapy group ( HR 1.30 , 95 % CI 0.80-2 .11 , p = 0.29 ) ; in LUX-Lung 6 , it was 19.6 months ( 95 % CI 17.0-22 .1 ) versus 24.3 months ( 19.0-27 .0 ) , respectively ( HR 1.22 , 95 % CI 0.81-1 .83 , p = 0.34 ) .\